obrixtamig + ezabenlimab

**Obrixtamig + ezabenlimab** is an investigational intravenous combination regimen under clinical evaluation as an antineoplastic immunotherapy for patients with advanced or metastatic Delta-like ligand 3 (DLL3)-positive small cell lung cancer (SCLC) and neuroendocrine tumors. - **Obrixtamig** (BI 764532) is an IgG-like bispecific T-cell engager antibody that simultaneously binds to DLL3, a tumor-associated antigen highly expressed in high-grade neuroendocrine carcinomas, and to CD3 on T cells, facilitating T cell-mediated cytotoxicity against DLL3-expressing tumor cells. - **Ezabenlimab** (BI 754091) is a humanized monoclonal antibody targeting the immune checkpoint PD-1 (programmed cell death protein 1) to enhance antitumor immune responses by inhibiting PD-1/PD-L1-mediated immunosuppression. The combination aims to leverage direct T cell engagement at the tumor site and systemic immune activation by checkpoint inhibition. Developed by Boehringer Ingelheim, this regimen is being tested in Phase 1/2 clinical studies for safety, tolerability, and efficacy in patients with relapsed or refractory DLL3-positive SCLC and neuroendocrine neoplasms unresponsive to standard therapies[1][2][3][5][7][9].

Brand names

obrixtamig + ezabenlimab

Other names

BI 764532 + BI 754091